<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21776">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02010112</url>
  </required_header>
  <id_info>
    <org_study_id>DM-MPBA-0813</org_study_id>
    <nct_id>NCT02010112</nct_id>
  </id_info>
  <brief_title>Bag Mode BreathID Hp Validation Versus Endoscopy in Detection of Helicobacter Pylori</brief_title>
  <official_title>Clinical Validation Study to Evaluate Presence of H. Pylori With 13C-Urea Breath Test Using the Dual Mode BreathID® Hp System Compared to Congruent Biopsy Results</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Exalenz Bioscience LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Exalenz Bioscience LTD.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A new method of breath collection for testing for Helicobacter Pylori infection has been
      developed by Exalenz. In this study, it will be compared to the gold standard- endoscopy
      results to prove its accuracy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will validate a breath collection method by comparing a newly developed breath
      test kit, IDkit:Hp™ TWO using breath collection bags, to congruent biopsy results (a
      composite reference standard by analyzing specimens with microbial culture, histological
      examination and rapid urease test- RUT) in detecting H.Pylori
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>overall percent agreement</measure>
    <time_frame>21 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary study endpoint is the performance measure (overall percent agreement) in initial diagnosis (presence/ absence of H.pylori) between biopsy results and bag mode breath test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall percent agreement</measure>
    <time_frame>21  days</time_frame>
    <safety_issue>No</safety_issue>
    <description>The performance measure (overall percent agreement) in post-therapy diagnosis (presence/ absence of H.pylori) between the Dual Mode BreathID® Hp System when using only one pair of IDkit:Hp™ TWO breath collection bags measured within 9 days and congruent biopsy results</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">161</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>Initial Diagnosis Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with clinical indication  of H.pylori infection will undergo breath test compared to routine clinical standard of care- endoscopy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Breath Test Collection bags</intervention_name>
    <description>Breath Collection bags will be used to collect breath of subjects before and after ingestion of 13-C breath test substrate</description>
    <arm_group_label>Initial Diagnosis Cohort</arm_group_label>
    <other_name>IDKit Two</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Present with clinical indication of H. pylori and candidate for upper endoscopy

          -  Have the ability and willingness to sign the Informed Consent Form for initial
             diagnosis cohort

          -  Naive to treatment in the past 18 months

          -  No known H.pylori status (no conclusive test results within last 6 months)

        Exclusion Criteria:

          -  Participation in other interventional trials

          -  Antibiotics and/or Bismuth preparations within four (4) weeks prior to breath test

          -  PPI (proton pump inhibitors) or H2 blockers within two (2) weeks prior to breath test

          -  Pregnant or breastfeeding women

          -  Allergy to test substrates
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dan Peres, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Exalenz Bioscience  Director of Clinical Affairs</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Avraham Hershkowitz, Msc.</last_name>
    <phone>+972-546605412</phone>
    <email>avrahamh@exalenz.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gil Guggenheim, BSc.</last_name>
    <phone>+972-89737514</phone>
    <email>gilg@exalenz.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Digestive Disease Associates, PA</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seema Shahi, RN</last_name>
      <phone>410-737-0053</phone>
      <email>s.shahi@ddamd.com</email>
    </contact>
    <investigator>
      <last_name>Vijay Narayen, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Metropolitan Gastroenterology Group</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cindy Coates, BS, CCRC</last_name>
      <phone>301-652-5520</phone>
      <email>cindy.coates@capitaldigestivecare.com</email>
    </contact>
    <contact_backup>
      <last_name>Shalee Blakeney</last_name>
      <phone>301-652-5520</phone>
      <email>shalee.blakeney@capitaldigestivecare.com</email>
    </contact_backup>
    <investigator>
      <last_name>Robert Hardi, M.D., CPI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48377</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Fleckenstein, RN</last_name>
      <phone>248-344-2364</phone>
      <email>rflecke1@hfhs.com</email>
    </contact>
    <contact_backup>
      <last_name>Dana Drysdale</last_name>
      <phone>248-344-2364</phone>
    </contact_backup>
    <investigator>
      <last_name>Amit Bhan, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Digestive Health Care</name>
      <address>
        <city>Ocean Springs</city>
        <state>Mississippi</state>
        <zip>39564</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luan Brown, RN</last_name>
      <phone>228-872-6291</phone>
      <email>Lbrowndhc@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Alfred E. McNair, Jr., M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Hospital</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mustafa Alani, MD</last_name>
      <phone>347-671-8231</phone>
      <email>malani@montefiore.org</email>
    </contact>
    <contact_backup>
      <last_name>Mortadha Abd, MD</last_name>
      <phone>347-671-8231</phone>
      <email>malani@montefiore.org</email>
    </contact_backup>
    <investigator>
      <last_name>Daniel Behin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Omega Medical Research</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johnna Pezullo, BSN, RN</last_name>
      <phone>401-739-9350</phone>
      <phone_ext>228</phone_ext>
      <email>Johnna@omegamedicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Eric B Newton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bon Secours Health System</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chantelle Lands, RN, MSN</last_name>
      <phone>804-928-3335</phone>
      <email>chantelle_lands@bshsi.org</email>
    </contact>
    <contact_backup>
      <last_name>Denise Doyle</last_name>
      <phone>804-594-3070</phone>
      <email>Denise_Doyle@bshsi.org</email>
    </contact_backup>
    <investigator>
      <last_name>Bimaljit Sandhu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 19, 2014</lastchanged_date>
  <firstreceived_date>December 5, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>H.Pylori</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
